跳至主要内容
临床试验/CTRI/2022/04/042308
CTRI/2022/04/042308进行中(未招募)4 期

An open label, observational, practice based, non-comparative, multicenter, prospective, active surveillance to evaluate the safety and tolerability of Bosentan 62.5mg/125mg oral tablets in patients with Pulmonary Arterial Hypertension (PAH) [WHO Group I].

Cipla Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
Cipla Ltd

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1. A written, signed, dated and ethics committee approved
  • informed consent form (data sharing consent) from patient
  • and/or legally acceptable representatives
  • 2. Either male or female of age 12 years and above
  • 3. Patient with the confirmed diagnosis of PAH (Group I)
  • with WHO Class III to IV symptoms

排除标准

  • 1. Contraindications to Bosentan or any of its components
  • 2. Hypersensitivity to Bosentan or any of its components
  • 3. Pregnancy and/or breastfeeding
  • 4. Co-administration of drugs such as Cyclosporine A or

研究者

发起方
Cipla Ltd

相似试验